Market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights are among the key offerings featured in The Business Research Company’s 2026 market reports, designed to deliver more actionable and strategically valuable research.
Dengue Vaccine Market Growth Outlook: How Much Bigger Will The Market Be By 2030?
The dengue vaccine market has experienced substantial expansion in recent years. Projections indicate it will advance from $0.51 billion in 2025 to $0.61 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 20.2%. Historically, this market growth stemmed from factors such as increasing dengue infection rates, the initial limited availability of vaccines, a growing public health burden, heightened awareness of mosquito-borne diseases, and early governmental intervention programs.
The dengue vaccine market is projected to experience substantial expansion over the coming years, reaching $1.16 billion in 2030 at a compound annual growth rate (CAGR) of 17.3%. This anticipated rise during the forecast period is driven by several factors, including the broadening of immunization initiatives, increased funding directed towards vaccine research, a surge in healthcare expenditure within endemic nations, a heightened emphasis on the effectiveness of multi-strain vaccines, and expedited regulatory clearances. Key developments shaping the market during this time encompass an escalating global commitment to preventing dengue, the proliferation of government-sponsored vaccination campaigns, the increasing uptake of tetravalent dengue vaccines, an expansion of public health financing in affected regions, and a growing need for immunization solutions tailored for children.
Request A Free Dengue Vaccine Market Sample From The Business Research Company:
How Is The Key Growth Driver Influencing The Dengue Vaccine Market?
The escalating number of dengue fever cases is anticipated to spur the growth of the dengue vaccine markets moving forward. Dengue fever is a viral infection transmitted by Aedes aegypti mosquitoes, which leads to symptoms like high fever, headaches, joint pain, and rashes. The increase in dengue fever incidents is attributed to climate change, urbanization, inadequate mosquito control measures, and viral evolution. The dengue vaccine operates by activating the immune system to recognize and fight the dengue virus. It reduces the intensity of the infection and minimizes the risk of severe complications, contributing to a decrease in cases and hospitalizations. For instance, in May 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, in the American region, dengue cases surpassed 7 million in April 2024, from 4.6 million cases reported in 2023. Therefore, the growing count of dengue fever cases is driving the expansion of the dengue vaccine market.
Dengue Vaccine Market Segmentation By Category: What Does The 2026 Report Cover?
The dengue vaccine market covered in this report is segmented –
1) By Type: Live Attenuated Vaccine, Chimeric Live Attenuated Vaccine, Inactivated Vaccine, Subunit Vaccine, Nucleic Acid Based Vaccine
2) By Vaccine Phase: Phase I, Phase II, Phase III
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By End-User: Hospitals, Clinics, Government Institutes, Non-Governmental Organizations, Other End-Users
Subsegments:
1) By Live Attenuated Vaccine: Single Strain, Multi-Strain
2) By Chimeric Live Attenuated Vaccine: Tetravalent Chimeric Vaccine, Monovalent Chimeric Vaccine
3) By Inactivated Vaccine: Whole Virus Inactivated Vaccine, Split Virus Vaccine
4) By Subunit Vaccine: Recombinant Protein Vaccine, Peptide-Based Vaccine
5) By Nucleic Acid Based Vaccine: DNA Vaccine, mRNA Vaccine
How Are Industry Players Changing The Dengue Vaccine Market Landscape?
Leading companies in the dengue vaccine market are concentrating on conducting clinical trials to develop innovative formulations, such as live attenuated vaccines, with the aim of providing broad, long-lasting protection against all four dengue virus serotypes. Live attenuated vaccines are derived from a weakened form of the virus that does not cause illness in healthy individuals but effectively stimulates the immune system to develop robust, sustained, and wide-ranging protection, allowing the body to recognize and combat the actual virus efficiently if exposed in the future. For instance, in June 2025, Merck & Co. Inc., a US-based pharmaceutical company, commenced the MOBILIZE-1 Phase 3 clinical trial to evaluate V181, its investigational live attenuated quadrivalent dengue vaccine. This study intends to enroll approximately 12,000 healthy children and adolescents aged 2 to 17 in dengue-endemic countries across the Asia-Pacific region, specifically Indonesia, Malaysia, Philippines, Singapore, Thailand, and Vietnam. The trial is structured as a randomized, double-blind, placebo-controlled study designed to assess the safety, immunogenicity, and efficacy of a single dose of V181 against all four dengue virus serotypes, regardless of any prior dengue exposure. The vaccine targets symptomatic dengue of any severity, including severe forms that may require hospitalization, striving to offer broad, long-lasting protection to alleviate the global burden of this rapidly spreading mosquito-borne disease.
Dengue Vaccine Market Global Key Players And Competitive Overview
Major companies operating in the dengue vaccine market are Merck & Co. Inc., Sanofi Pasteur Limited, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Biological E. Limited, Saint Louis University, Indian Immunologicals Limited, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Instituto Butantan, Bharat Biotech Ltd., Panacea Biotec Limited, SABIN Vaccine Institute, Medigen Vaccine Biologics Corporation, Emergex Vaccines Holding Ltd., BioNet-Asia Co. Ltd., Codagenix Inc., KM Biologics Co. Ltd., Chula Vaccine Research Center, Imutex Ltd.
Explore Comprehensive Dengue Vaccine Market Coverage In The Full Report:
Regional Analysis Of The Dengue Vaccine Market: Where Is The Industry Concentrated?
Asia-Pacific was the largest region in the dengue vaccine market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the dengue vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.
